Immune Reconstitution and Early Infectious Complications Following Nonmyeloablative Hematopoietic Stem Cell Transplantation

Abstract Non-myeloablative stem cell transplantation (NMT) has been increasingly used in compromised patients who would otherwise have been unable to undergo allotransplant. There is little understanding of the kinetics of immune reconstitution and its influence on infective complications following NMT. The aim of present study was to evaluate lymphocyte subset reconstitution over the first 12 months post-transplant in 15 adult patients receiving NMT with comparison to that of 30 patients grafted with a conventional hemopoietic stem cell transplantation (HSCT). NMT recipients were conditioned with fludarabine-based conditioning regimens. Peripheral blood stem cell (PBSC) was the source of stem cells in 13 NMT recipients and in 24 conventional HSCT recipients. Absolute numbers of helper (CD4+) T cells, naive (CD4+ CD45RA+) and memory (CD4+ CD45RO+) T cells as well as suppressor (CD8+) T cells, CD19+ B cells and NK cells were comparable in the two groups at all time points after transplantation. A median value of 200 CD4+ T cells/μl was achieved at 2 months post-transplant by the NMT and HSCT recipients. The CD4:CD8 ratio remained severely depressed throughout the study period. Almost all CD4+ lymphocytes expressed CD45RO antigen in the both groups of patients B lymphocytes showed low counts throughout the entire study period in both groups. Bacteremia and CMV antigenemia occurred respectively in 13 and 36% of the patients in the NMT group and in 15 and 39% of the patients in the HSCT group. Our preliminary data indicate that patients receiving a NMT have a lymphocyte reconstitution similar to that observed in patients who received a conventional HSCT. The incidence of bacteremia and CMV infection were not significantly different between the groups. Nevertheless, due to the small sample size, these results should be considered suggestive rather than definitive.

[1]  E. Spierings,et al.  Histocompatibility. , 2018, Transplantation proceedings.

[2]  J. Garcia-conde,et al.  Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. , 2002, Blood.

[3]  M. Maris,et al.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[5]  D. Rizzieri,et al.  Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  J. Mary,et al.  Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients , 2001, British journal of haematology.

[7]  J. Wagner,et al.  Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  B. Bolwell,et al.  Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.

[9]  D. Douek,et al.  Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism , 2001, Bone Marrow Transplantation.

[10]  C. Solano,et al.  Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.

[11]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[12]  R. Childs,et al.  CMV reactivation in nonmyeloablative HSCT , 2001, Bone Marrow Transplantation.

[13]  C. Siegrist,et al.  Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. , 2000, Blood.

[14]  R. Bouabdallah,et al.  High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation , 2000, Bone Marrow Transplantation.

[15]  R. Naumann,et al.  Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin , 2000, Bone Marrow Transplantation.

[16]  C. Payá,et al.  Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients , 2000, Clinical transplantation.

[17]  R. Vij,et al.  Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[20]  Gregory T Stelzer,et al.  U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. , 1997, Cytometry.

[21]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[22]  H. Grosse-wilde,et al.  Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. , 1996, Blood.

[23]  C. Mackall,et al.  T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. , 1993, Blood.

[24]  G. Heller,et al.  B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. , 1990, Blood.

[25]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[26]  Jaap M Middeldorp,et al.  Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. , 1985, Blood.

[27]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[28]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  D. Porter,et al.  High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  S. Mineishi,et al.  Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin , 2002, Bone Marrow Transplantation.